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A series  of  10  dose  conﬁrmation  studies  was  conducted  to evaluate  the  persistent  activity  of
an extended-release  injectable  (ERI)  formulation  of eprinomectin  against  single  point  chal-
lenge infections  of  gastrointestinal  and pulmonary  nematodes  of cattle.  The  formulation,
selected  based  on  the  optimal  combination  of  high  nematode  efﬁcacy,  appropriate  plasma
proﬁle, and satisfactory  tissue  residue  levels,  includes  5%  poly(d,l-lactide-co-glycolic)acid
(PLGA)  and  is designed  to deliver  eprinomectin  at a dose  of  1.0  mg/kg  bodyweight.  Indi-
vidual  studies,  included  16–30  cattle  blocked  based  on  pre-treatment  bodyweight  and
randomly  allocated  to treatment  with  either  ERI  vehicle  or  saline  (control),  or  the  selected
Eprinomectin  ERI  formulation.  Treatments  were  administered  once  at a dose  volume  of
1 mL/50  kg  bodyweight  by subcutaneous  injection  in  front of  the  shoulder.  In  each  study,
cattle  were  challenged  with  a combination  of infective  stages  of  gastrointestinal  and/or  pul-
monary nematodes  100,  120  or 150  days  after  treatment  and  were  processed  for parasite
recovery according  to  standard  techniques  25–30  days  after  challenge.  Based  on para-
site counts,  Eprinomectin  ERI (1 mg  eprinomectin/kg  bodyweight)  provided  >90%  efﬁcacy
(p < 0.05)  against  challenge  with  Cooperia  oncophora  and  Cooperia  surnabada  at  100  days
after treatment;  against  challenge  with  Ostertagia  ostertagi,  Ostertagia  lyrata,  Ostertagia  lep-
tospicularis, Ostertagia  circumcincta,  Ostertagia  trifurcata,  Trichostrongylus  axei,  and  Cooperia
punctata at  120  days  after  treatment;  and  against  challenge  with  Haemonchus  contortus,
Bunostomum  phlebotomum,  Oesophagostomum  radiatum  and  Dictyocaulus  viviparus  at 150
days after  treatment.  Results  of a study  to evaluate  eprinomectin  plasma  levels  in cattle
treated  with  the  Eprinomectin  ERI  formulation  reveal  a  characteristic  second  plasma  con-
centration peak  and  a proﬁle  commensurate  with  the  duration  of  efﬁcacy.  These  results
conﬁrm that  the Eprinomectin  ERI  formulation  can  provide  high  levels  of parasite  control
emato
 against a  range  of  n
. IntroductionEprinomectin is a highly effective parasiticide devel-
ped as a broad-spectrum endectocide for topical
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treatment of cattle of all classes and ages. It is a semi-
synthetic compound of the avermectin family originally
selected as a nematocide, insecticide, and miticide to be
administered by the topical route (Shoop et al., 1996; Shoop
Open access under CC BY-NC-ND license.and  Soll, 2002). The commercialized eprinomectin topical
formulation (0.5 mg  eprinomectin/kg bodyweight) has a
persistent  activity of at least four weeks against the most
important bovine nematodes (Cramer et al., 2000; Holste
 Parasito314 M.D. Soll et al. / Veterinary
et al., 2002) and has therefore been used successfully in
strategic programs to control gastrointestinal nematodes
and lungworm in cattle (Batty et al., 1999; Epe et al., 1999;
Dorny et al., 2000).
In order to extend the inherent persistent nemato-
cidal activity of eprinomectin, a program was initiated
to develop an injectable formulation which would make
the compound available for an extended period of time
resulting in effective control of nematode infections in cat-
tle for a signiﬁcantly prolonged period compared to the
commercialized topical formulation. The suitability of epri-
nomectin as an injectable anthelmintic for cattle had been
reported previously based on exploratory studies using an
experimental propylene glycol/glycerol formal-based for-
mulation (Shoop et al., 2001).
Exploratory studies evaluated effects of the active ingre-
dient, organic and diluent solvents, and release matrix on
plasma levels and release proﬁle, tissue residues, and efﬁ-
cacy against nematodes. A pivotal dosage and formulation
determination study was  conducted subsequently to deter-
mine the optimal dosage of eprinomectin to be delivered
in the lead extended-release injection formulation.
This paper provides results of 10 studies conducted
to conﬁrm the duration of efﬁcacy of the selected epri-
nomectin extended-release injection against challenge
with a wide spectrum of gastrointestinal and/or pulmonary
nematodes at 100, 120 and/or 150 days following treat-
ment of cattle of several breeds at different geographical
locations. In addition, results of a study conducted to con-
ﬁrm the plasma proﬁle of the formulation are provided.
2. Materials and methods
A total of 10 controlled dose conﬁrmation studies
were conducted to conﬁrm the duration of efﬁcacy of the
selected formulation, ﬁve in the USA, one in the UK, and
four in Germany. Study numbers 1 and 2 were designed to
evaluate efﬁcacy in groups of cattle challenged either 100
or 120 days after treatment. Studies 3–8 employed chal-
lenge 120 days after treatment only, and study numbers
9 and 10 were designed to evaluate efﬁcacy against chal-
lenge 150 days after treatment. The studies were designed
and conducted in compliance with the regulatory require-
ments of both the FDA/CVM and the European Medicines
Agency/Committee for Medicinal Products for Veterinary
Use, and according to relevant guidelines for Good Clinical
Practices (GCPs) and for establishing the efﬁcacy of cattle
anthelmintics (Vercruysse et al., 2001).
The studies were performed as blinded studies, i.e., all
personnel involved in collecting data were masked to the
treatment assignment of the animals.
An additional study also was conducted under good lab-
oratory practice to generate data conﬁrming the plasma
proﬁle of eprinomectin B1a in cattle treated with the ﬁnal
eprinomectin extended-release injection formulation.
2.1. Efﬁcacy studies2.1.1. Experimental animals
A total of 198 (112 male, 34 male castrate and 52
female) healthy, ruminating Angus, Angus cross, Braunviehlogy 192 (2013) 313– 320
(Brown Swiss), Charolais, Charolais cross, Fleckvieh (Sim-
mental), Holstein, Limousin, Limousin cross or Pinzgauer
cattle, weighing 87–276 kg prior to treatment, and aged
approximately 4–11 months were included in the ten efﬁ-
cacy studies conducted in the USA (Studies 1, 2, 5, 6, and
9), the UK (Study 3), and Germany (Studies 4, 7, 8, and 10).
Details of the cattle included in each study are provided in
Table 1. Animals had not been treated previously with an
avermectin or milbemycin product.
At study inception, animals included in Studies 1–5 and
7–10 were worm-free (as determined by fecal examination
prior to study start), with the exception of some animals in
Study 2, which shed Strongyloides eggs. Cattle in Studies
3, 4, 7, 8 and 10 were nematode-naïve, while cattle used
in Studies 1, 2, 5 and 9 were treated with fenbendazole
(10 mg/kg) at an appropriate time before pre-treatment
fecal examination. The animals used in Study 6 harbored
naturally acquired nematode infections and shed up to 321
strongylid eggs per gram of feces on Day −7.
Animals in Studies 1–5 and 7–10 were held indoors or
in partially covered, open-sided pens (Study 2) through-
out the study period under conditions designed to preclude
unintentional nematode infections. The animals were fed
according to local practice, with the same feed available
for each animal within each study. Animals in Study 6
grazed naturally contaminated pasture for 120 days after
which they too were housed under conditions designed to
preclude further nematode exposure and fed as per local
practice. Drinking water was available to all animals in all
studies at all times.
All animals were handled with due regard to their wel-
fare and in compliance with Merial Institutional Animal
Care and Use Committee (IACUC) approvals, any applicable
local regulations, and requirements of any local IACUC.
2.1.2. Study design
All studies were conducted under a randomized block
design with replicates formed based on pre-treatment
bodyweights.
For both of Studies 1 and 2, a total of 30 cattle were
ranked by pre-treatment bodyweight and grouped into
replicates of three animals each and randomly allocated
to one of three treatment groups: a vehicle treated con-
trol group, a group treated with Eprinomectin 5% (w/v)
ERI (1 mg  eprinomectin/kg bodyweight) on Day 0; or a
group treated with Eprinomectin 5% (w/v) ERI (1 mg epri-
nomectin/kg bodyweight) on Day 20; 10 animals per
treatment group in each study. All groups in each study
were subsequently challenged with nematodes on the
same day (Day 120), allowing for evaluation of efﬁcacy 100
or 120 days after treatment.
For each of Studies 3, 4, 5, 7 and 9, replicates of
two  cattle each were formed sequentially. Within repli-
cates, animals were randomly allocated to one of two
treatment groups: control (vehicle/saline-treated) group or
Eprinomectin 5% (w/v) ERI (1 mg  eprinomectin/kg body-
weight) group; with eight or ten animals per treatment
group. Animals were challenged on Day 120.
For Study 6, a total of 75 cattle were ranked by pre-
treatment bodyweight, grouped into replicates of ﬁve
animals each, and randomly allocated to one of ﬁve
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Table 1
Details of cattle included in the efﬁcacy studies.
Study Treatment/animals per treatment Breed Sex ∼Age (months) Pre-treatment
bodyweight (kg)
1
Controla n = 10
Holstein Male 4
87
–121
EpERI  5%b n = 10
EpERI 5% n = 10
2
Control n = 10
Angus Female 5
180
–252
EpERI 5% n = 10
EpERI 5% n = 10
3
Control n = 10 Limousin, Limousin
cross
Male castrate
5
–7
154
–191EpERI 5% n = 10
4
Control n = 10
Pinzgauer Male
5
–6
152
–210EpERI 5% n = 10
5
Control n = 10
Holstein Male 5.5
153
–194EpERI  5% n = 10
6
Control n = 15 Angus, Angus cross,
Charolais, Charolais cross
6 male castrate, 24
female
9
–11
190
–276EpERI  5% n = 15
7
Control n = 8 Fleckvieh
(Simmental) Male
5
–6
164
–197.5EpERI 5% n = 8
8
Control n = 10 Fleckvieh
(Simmental) Male
4
–6
147
–196EpERI 5% n = 10
9
Control n = 8
Angus, Angus cross 8 male castrate, 8
female
6
–7
148
–183EpERI  5% n = 8
10
Control n = 8 Braunvieh (Brown
Swiss) Male 6
128
–168EpERI 5% n = 8
a Control = ERI vehicle (Studies 1–6) – or saline-treated (Studies 7–10).
b EpERI = Eprinomectin 5% ERI formulation (1 mg  eprinomectin/kg bodyweight).
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treatment groups: control (vehicle-treated) group; Epri-
nomectin 5% (w/v) ERI (1 mg  eprinomectin/kg bodyweight)
group; or one of 3 other formulations (for which data are
not presented here); 15 animals per treatment group.
For Studies 8 and 10, cattle were ranked by pre-
treatment bodyweight, grouped into replicates of three
animals each and randomly allocated to one of three treat-
ment groups: control (saline-treated) group; Eprinomectin
5% (w/v) ERI (1 mg  eprinomectin/kg bodyweight) group; or
to an additional treatment group (data not shown); eight
or twelve animals per treatment group. Animals were chal-
lenged with nematodes on Day 150.
All treatments, vehicle (formulation that consisted of
the excipients of Eprinomectin ERI formulation) (Studies
1–6) or saline (Studies 7–10) as well as Eprinomectin ERI,
were administered at a dose of 1 mL/50 kg (1 mL/110 lb)
bodyweight once on Day 0 (all studies) or Day 20 (2 addi-
tional groups in Studies 1 and 2) by subcutaneous injection
in front of the shoulder using commercial syringes and nee-
dles. All cattle were observed hourly for 4 h post-treatment
and thereafter once daily throughout the studies for health
problems or adverse drug events.
Study animals were challenged with infective stages of
gastrointestinal and pulmonary nematodes 100, 120 or 150
days after treatment. They were humanely euthanized and
processed for nematode recovery 25–30 days after chal-
lenge.
2.1.3. Induced nematode infections
Cattle in Studies 1–8 were inoculated with infec-
tive stages of a combination of several of the following
nematode species: Haemonchus contortus, Haemonchus
placei, Haemonchus spp., Ostertagia ostertagi/lyrata,
Ostertagia leptospicularis,  Ostertagia spp. (ovine), Tri-
chostrongylus axei, Trichostrongylus colubriformis, Cooperia
oncophora/surnabada,  Cooperia punctata, Cooperia cur-
ticei, Nematodirus helvetianus, Bunostomum phlebotomum,
Oesophagostomum radiatum, Strongyloides papillosus,
Trichuris spp. (ovine), and/or Dictyocaulus viviparus (see
Table 2). Infective material was administered as a single
bolus 100 days (Studies 1 and 2) or 120 days (Studies
1–8) after treatment. Cattle in Studies 9 and 10 were
inoculated on Day 150 with a combination of infective
third-stage larvae of the following nematodes: H. contor-
tus, O. ostertagi/lyrata,  B. phlebotomum,  O. radiatum and D.
viviparus.
Parasites used were generally recent ﬁeld isolates as
deﬁned per VICH GL 7 (FDA Guidance 90), Effectiveness of
anthelmintics: general recommendations. The number of
larvae given was in accordance with the W.A.A.V.P. Guide-
lines for Testing of Anthelmintics in Ruminants (Wood
et al., 1995). The actual nematode species inoculated and
numbers of larvae/eggs administered to each animal in
each study are shown in Table 2.
For all nematode species apart from B. phlebotomum
and S. papillosus,  suspensions of larvae/eggs were adminis-
tered by oral gavage. To induce B. phlebotomum infections,
third-stage larvae were administered topically between
the shoulder blades or applied into the external auditory Ta
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recorded as ≤LOD were converted to 0.50 ng/mL.M.D. Soll et al. / Veterinary
anal. Infective larvae of S. papillosus were injected subcu-
aneously.
.1.4. Parasite counts
At necropsy, the lungs (with trachea) (Studies 1, 3, 4, 5,
, and 10), abomasum and small intestine (Studies 1–10),
nd large intestine (Studies 3, 4, 5, 9, and 10) were removed.
otal lungworms were collected and counted. The contents
f the abomasum, small intestine, and large intestine were
ollected separately. Abomasum and small intestine also
ere incubated (saline soak) to recover mucosal stages of
he parasites for identiﬁcation and counting. The entire
ontents or a known percentage of each organ (aboma-
um and small intestine contents and soaks: 5%, 10% or 25%
liquots, or total counts; large intestine contents: 20% or
5% aliquots or total count) were examined and the appro-
riate dilution factor applied for ﬁnal count. To facilitate
solation and counting of nematodes, organ contents and
oaks were screened over sieves of appropriate mesh sizes
o remove the debris.
Counts of each parasite species for each animal were
alculated by multiplying the number of worms actually
ounted in each location by the aliquot factor and summing
ver locations.
Nematodes were identiﬁed to species or genus level,
ex, and stage of development according to recognized
ethods and procedures. Adult female nematodes and/or
ourth-stage larvae were not always identiﬁed to species
evel. For some genera of nematodes (e.g., Cooperia, Osterta-
ia,  and Trichostrongylus), the total counts were estimated
y proportionally assigning adult females to each species
ased on the adult male counts. When adult females
ithin genera were counted in the presence of no males,
he counts were either proportioned equally or assigned
ccording to a ratio based on the species present in
ther animals. For Trichostrongylus spp. in one study, non-
peciated nematodes were assigned to species based on the
ocation in which the nematodes were found.
.1.5. Statistical methods
Nematode counts were transformed to the natural log-
rithm of (count + 1) for calculation of geometric means.
fﬁcacy was calculated as 100[(C − T)/C], where C is the geo-
etric mean for the control group and T is the geometric
ean for the Eprinomectin ERI treated group(s).
For the dose conﬁrmation Studies 1–10, all nema-
ode species which occurred in two or more studies were
ncluded in a combined analysis based on the time of the
hallenge in relation to treatment as follows: challenge 100
ays post-treatment, Studies 1 and 2 (groups treated on
ay 20); challenge 120 days post-treatment, Studies 1 and
 (groups treated on Day 0) plus Studies 3–8; challenge
50 days post-treatment, Studies 9 and 10. Overall efﬁ-
acy was calculated as percent reduction in worm counts as
00[(C − T)/C], where C is the overall geometric mean of the
ehicle or saline (control)-treated group and T is the overall
eometric mean of the Eprinomectin ERI-treated group.Nematode counts were analyzed using Friedman’s test,
 nonparametric method based on ranks within blocks.
ndividual studies were considered to be blocks for this
ombined analysis. Analysis of variance (ANOVA) methodlogy 192 (2013) 313– 320 317
based on the rank-transformed data was used for Fried-
man’s test, which is the nonparametric analog of the
two-way ANOVA. The PROC MIXED procedure of SAS®1
Version 9.1 was  used with treatment as a ﬁxed effect and
individual study as a random effect. A two-sided signiﬁ-
cance level of 0.05 was used for all tests.
For nematodes which were observed in one of the
studies only, the control group was  compared to the Epri-
nomectin ERI treatment group using the Wilcoxon rank
sum test. A two-sided test was used at the signiﬁcance level
of 0.05.
2.2. Plasma proﬁle study
A total of 21 male castrate and 21 female healthy, rumi-
nating Angus or Angus cross cattle were enrolled in the
plasma proﬁle determination study. They were 8–9 months
of age and weighed between 147 and 247 kg at the time of
treatment. They were held in dry lots or paddocks with pas-
ture. Six of the 42 animals (3 male castrates and 3 females)
were removed from the study cohort before Day 161 for a
different purpose.
The cattle in this study (Study 11) were treated with
the ﬁnal formulation of Eprinomectin 5% (w/v) ERI, admin-
istered at 1 mL/50 kg bodyweight once on Day 0 by
subcutaneous injection in front of the shoulder using com-
mercial syringes and needles. Blood samples were collected
at approximately 6 h post dose (0.25 Day) and daily dur-
ing the ﬁrst seven days after treatment. Samples were then
collected on Days 10, 14, and 21. From Day 21 through Day
161, blood was  drawn at two-week intervals. Plasma sam-
ples were harvested from the blood for analyses using a
method employing high pressure liquid chromatography
(HPLC) with ﬂuorescence detection (unpublished).
The analytical method for determination of epri-
nomectin (B1a) in plasma was  validated before use in
this study. The plasma samples were mixed with internal
standard solution [MK-0324, Merck Research Labora-
tories, ∼25 ng/mL in acetonitrile (ACN)] and extracted
with ACN. One milliliter of the clear extract was evap-
orated to dryness and reconstituted in 150 L 30%
1-N-methylimidazole/ACN. The remainder of the isolation,
derivatization and quantiﬁcation procedures for plasma
samples were similar to the method used for deter-
mination of eprinomectin levels in bovine milk using
a HPLC equipped with ﬂuorescent detection (Pollmeier
et al., 2002). The validated limit of quantitation (LOQ) was
0.75 ng/mL, and the limit of detection (LOD) was 0.50 ng/mL
for eprinomectin B1a (main component of eprinomectin).
For each of the sampling time points between the earli-
est collection on Day 0.25 and the collection on Day 161, the
mean and standard error of the mean of the plasma epri-
nomectin B1a concentration data from the animals were
calculated and plotted. Prior to calculation, values recorded
as ≤LOQ but >LOD were converted to 0.75 ng/mL, and those1 All marks are property of their respective owners.
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Table 3
Efﬁcacy of Eprinomectin ERI against challenge infections with gastrointestinal nematodes 100 days after treatment.
Species No. of studies Control animal prevalenced Geometric meana nematode count Efﬁcacyb (%) p-Valuec
Control (vehicle) Eprinomectin ERI
Trichostrongylus axei 2 20/20 644.4 1.7 >99 <0.01
Cooperia oncophora 2 18/20 648.5 4.2 >99 <0.01
Cooperia surnabada 1 9/10 671.9 1.0 >99 <0.01
Cooperia punctata 2 20/20 3025.8 3.2 >99 <0.01
a Geometric mean counts (based on transformation to the natural logarithm of [count + 1]).
tin ERI)
 Wilcox
levant stb Efﬁcacy = 100 [(geometric mean control −geometric mean Eprinomec
c Probability from Friedman’s test (species occurring in two  studies) or
d Number of control cattle infected/total number of control cattle in re
3. Results
The results of the two studies which evaluated the
persistent efﬁcacy of Eprinomectin ERI against a single
challenge with infective stages of selected gastrointestinal
nematodes at 100 days after treatment are summarized in
Table 3. Cattle treated with Eprinomectin ERI had signiﬁ-
cantly (p < 0.01) fewer of the following nematodes than the
vehicle-treated controls with overall reduction of nema-
tode counts by >99%: C. oncophora,  C. surnabada,  Cooperia
punctata, and T. axei.
The results of the eight studies conducted to conﬁrm
the persistent efﬁcacy of Eprinomectin ERI against a single
challenge with infective stages of a wide range of gas-
trointestinal nematodes and/or lungworm at 120 days after
treatment are summarized in Table 4. Cattle treated with
Eprinomectin ERI had signiﬁcantly (p < 0.05) fewer of the
following nematodes than the vehicle/saline-treated con-
trols with an overall reduction of nematode counts of ≥92%:
H. contortus, O. lyrata,  O. ostertagi, O. leptospicularis,  O. cir-
cumcincta, O. trifurcata, T. axei, C. punctata, B. phlebotomum,
Table 4
Efﬁcacy of Eprinomectin ERI against challenge infections with gastrointestinal an
Species No. of studies Control animal
prevalencef
Geo
Con
Haemonchus contortus 1 10/10 1
Haemonchus placei 2 19/19 2
Ostertagia lyrata 3 20/30 
Ostertagia ostertagi 6 58/58 30
Ostertagia leptospicularis 1 10/10 55
Ostertagia circumcincta 1 10/10 3
Ostertagia trifurcata 1 8/10 
Trichostrongylus axei 7 74/74 10
Trichostrongylus colubriformis 3 21/31 
Cooperia oncophora 8 63/83 2
Cooperia surnabada 6 47/58 1
Cooperia punctata 7 64/74 10
Cooperia curticei 1 10/10 13
Bunostomum phlebotomum 2 19/19 
Nematodirus helvetianus 4 41/48 1
Oesophagostomum radiatum 3 24/28 
Trichuris discolore 2 8/19 
Dictyocaulus viviparus 3 28/28 1
a Geometric mean counts (based on transformation to the natural logarithm of
b Efﬁcacy = 100 [(geometric mean control − geometric mean Eprinomectin ERI)
c Probability from Friedman’s test (species occurring in two  or more studies) o
d Not signiﬁcant at  ˛ = 0.05.
e Naturally acquired infections.
f Number of control cattle infected/total number of control cattle in relevant st/geometric mean control].
on rank sum test (species occurring in one study only).
udies.
O.  radiatum, and D. viviparus; overall reduction of H. placei,
C. oncophora,  C. surnabada and N. helvetianus counts ranged
from 83% to 88% (p < 0.01).
The results of the two  studies conducted to conﬁrm
the persistent efﬁcacy of Eprinomectin ERI against a sin-
gle challenge of infective stages of selected gastrointestinal
nematodes and lungworm at 150 days after treatment
are summarized in Table 5. Cattle treated with Epri-
nomectin ERI had signiﬁcantly (p < 0.01) fewer of the
following nematodes than the vehicle/saline-treated con-
trols with an overall reduction of nematode counts by
≥92%: H. contortus, B. phlebotomum,  O. radiatum, and
D. viviparus; the overall reduction of O. ostertagi was
80% (p < 0.01).
Upon examination of contents of organs collected at
necropsy, H. contortus and T. axei in Study 3 and S. papillo-
sus, Oesophagostomum venulosum and Trichuris spp. (ovine)
in Study 4 did not become established in the controls. The
counts of Trichuris discolor recovered in Studies 5 and 6
(see Table 4) are considered to be from naturally acquired
infections.
d pulmonary nematodes 120 days after treatment.
metric meana nematode count Efﬁcacyb (%) p-Valuec
trol (vehicle/saline) Eprinomectin ERI
32.2 0.7 >99 <0.05
83.2 47.5 83 <0.01
12.1 0.9 92 <0.01
91.3 16.8 >99 <0.01
53.7 39.6 >99 <0.05
12.5 2.8 >99 <0.05
14.9 0 100 <0.05
02.1 63.4 94 <0.01
22.8 10.1 56 nsd
19.8 32.1 85 <0.01
40.3 16.7 88 <0.01
10.7 42.9 96 <0.01
26.8 104.6 92 ns
47.8 0.2 >99 <0.01
97.4 27.5 86 <0.01
39.9 0.3 >99 <0.01
2.2 0.1 96 <0.01
52.8 0.2 >99 <0.01
 [count + 1]).
/geometric mean control].
r Wilcoxon rank sum test (species occurring in one study only).
udies.
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Table  5
Efﬁcacy of Eprinomectin ERI against challenge infections with gastrointestinal and pulmonary nematodes 150 days after treatment.
Species No. of Studies Control animal
prevalenced
Geometric meana nematode count Efﬁcacyb (%) p-Valuec
Control (saline) Eprinomectin ERI
Haemonchus contortus 1 8/8 937.3 78.5 92 <0.01
Ostertagia ostertagi 2 16/16 5638.8 1153.8 80 <0.01
Bunostomum phlebotomum 2 16/16 174.7 5.0 97 <0.01
Oesophagostomum radiatum 2 16/16 206.1 4.4 98 <0.01
Dictyocaulus viviparus 2 16/16 138.0 1.4 99 <0.01
a Geometric mean counts (based on transformation to the natural logarithm of [count + 1]).
tin ERI)
 Wilcox
evant st
o
t
(
h
t
c
a
f
c
e
t
D
r
a
i
c
f
p
o
p
F
s
e
eb Efﬁcacy = 100 [(geometric mean control − geometric mean Eprinomec
c Probability from Friedman’s test (species occurring in two studies) or
d Number of control cattle infected/total number of control cattle in rel
All animals were reported as normal during regular
bservations for up to 4 h after treatment, indicating that
reatment, either with Eprinomectin ERI or vehicle/saline
control), was well accepted. There were no drug-related
ealth problems or adverse drug events reported at any
ime during the studies.
Some cattle, controls and Eprinomectin ERI treated
attle in Studies 3 and 5 were treated with antibiotics,
n anti-inﬂammatory drug, and/or respiratory stimulant
or respiratory symptoms/pulmonary disease during the
ourse of the studies. While most cattle made a full recov-
ry and completed the study, one control animal in each of
he two studies did not respond to treatment and died on
ays 58 and 77, respectively. In addition, ﬁbrinous pleu-
itis/and bloat were diagnosed at necropsy of two control
nimals in Study 9 on Days 122 and 150, respectively.
The plasma assay results from Study 11 are summarized
n Fig. 1. The 20 sampling points provided a comprehensive
haracterization of the plasma proﬁle of eprinomectin B1a
ollowing administration of Eprinomectin ERI to cattle. The
lasma proﬁle recorded is commensurate with the period
f expected efﬁcacy, and displays the characteristic second
lasma concentration peak.
ig. 1. Eprinomectin B1a plasma concentration versus time following a
ingle subcutaneous injection of Eprinomectin ERI at a dose rate of 1 mg
prinomectin per kg body weight in cattle (arithmetic mean ± standard
rror of the mean)./geometric mean control].
on rank sum test (species occurring in one study only).
udies.
4. Discussion
The series of 10 studies conducted at sites in the USA,
UK and Germany conﬁrm the high levels of efﬁcacy of the
Eprinomectin ERI formulation in treated cattle exposed
to nematode challenge 100, 120 and 150 days following
treatment, and this effect was evident against a variety of
local strains of gastrointestinal nematodes and lungworm.
A relationship was  observed between the different nema-
tode species and the minimum period of protection against
establishment in cattle at the 90% threshold level following
Eprinomectin ERI treatment. The durations were shortest
in C. oncophora and Cooperia surnabada,  and progressively
lengthened through T. axei, O. ostertagi, O. radiatum and
Bunostomum phlebotomum to Dictyocaulus viviparus. This
pattern resembles the ﬁndings of several studies with both
injectable and topical formulations of macrocyclic lactones,
and would appear to reﬂect the differences in inherent
susceptibility of various nematode species to this class of
compounds (Vercruysse and Rew, 2002).
The single challenge protocol allows for determina-
tion of efﬁcacy at a speciﬁc time point in relation to
treatment and is an appropriate method to determine pre-
cisely the extent of the duration of nematocidal activity
of anthelmintics. Multiple-inoculation challenge studies
designed to mimic  natural exposure result in an estimation
of efﬁcacy accumulated over a period of time, and studies
conducted according to these protocols may  not allow for
precise determination of the end of protection provided
by a treatment with persistent effect (Barth and Rehbein,
1997; Deroover et al., 1997). Studies conducted to eval-
uate the efﬁcacy of the Eprinomectin ERI formulation in
cattle exposed to natural challenge under grazing condi-
tions conﬁrm a similar duration of effect (Rehbein et al.,
2013a, 2013b; Kunkle et al., 2013).
In the selected extended-release formulation,
eprinomectin is incorporated in poly(d,l-lactide-co-
glycolic)acid (PLGA). This polymer has been demonstrated
to be a safe and effective biodegradable material which
has been used as a drug delivery system for extended
release applications of various pharmaceutical compounds
in human and veterinary medicines including macrocyclic
lactones (Lewis, 1990; Rathbone and Gurny, 2000; Clark
et al., 2004; Winzenburg et al., 2004). Following subcuta-
neous injection, eprinomectin is released from the matrix
formed with PLGA which degrades over time. The plasma
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proﬁle shows a unique characteristic of this formulation,
providing a second plasma concentration peak more than
70 days post dose.
The results of the plasma proﬁle study conﬁrm that
the formulation has a predictable release proﬁle which
supports the extended duration of effect demonstrated in
the efﬁcacy studies. Based on efﬁcacy data established in
terms of repeated fecal nematode egg and/or larval counts
in numerous studies with cattle under continuous nat-
ural challenge conditions (Kunkle et al., 2013; Rehbein
et al., 2013b), the levels of drug delivery between the
primary and secondary peaks can be expected to still
provide high levels of efﬁcacy against important nematode
species. This is further supported by the results of a con-
trolled study in which treatment with the Eprinomectin
ERI formulation was highly effective (99.7–100%, p < 0.01)
in preventing establishment of H. contortus, O. ostertagi, C.
oncophora, C. punctata, C. surnabada and N. helvetianus in
cattle challenged with these parasites 63 days after treat-
ment (Rehbein et al., unpublished results).
In conclusion, eprinomectin formulated as an extended-
release injectable was highly efﬁcacious in protecting cattle
from a variety of important nematode parasites when eval-
uated against single point challenges at 100, 120 or 150
days after treatment. These results from different geo-
graphic regions using cattle of several breeds challenged
with locally sourced parasites, together with the excellent
immediate efﬁcacy against established nematode infec-
tions (Hunter et al., 2013; Rehbein et al., 2013a)  and the
high levels of efﬁcacy observed in grazing cattle exposed
to naturally acquired nematode infections (Kunkle et al.,
2013; Rehbein et al., 2013b)  conﬁrm that Eprinomectin
ERI is a highly effective treatment that can provide control
of gastrointestinal and pulmonary nematode infections of
cattle for up to 150 days after a single injection.
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